OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!
If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.
Requested Article:
Metastatic Renal Cell Carcinoma: How to Make the Best Sequencing Decision After Withdrawal for Intolerance to a Tyrosine Kinase Inhibitor
Roberto Sabbatini, Cinizia Ortega, Giuseppe Procopio, et al.
Future Oncology (2013) Vol. 9, Iss. 6, pp. 831-843
Closed Access | Times Cited: 7
Roberto Sabbatini, Cinizia Ortega, Giuseppe Procopio, et al.
Future Oncology (2013) Vol. 9, Iss. 6, pp. 831-843
Closed Access | Times Cited: 7
Showing 7 citing articles:
Cross-resistance to clinically used tyrosine kinase inhibitors sunitinib, sorafenib and pazopanib
Kristy J. Gotink, Maria Rovithi, Richard R. de Haas, et al.
Cellular Oncology (2015) Vol. 38, Iss. 2, pp. 119-129
Open Access | Times Cited: 55
Kristy J. Gotink, Maria Rovithi, Richard R. de Haas, et al.
Cellular Oncology (2015) Vol. 38, Iss. 2, pp. 119-129
Open Access | Times Cited: 55
A Review of Interventional Clinical Trials in Renal Cell Carcinoma: A Status Report From the ClinicalTrials.gov WebSite
Matthew R. Zibelman, Peter Barth, Elizabeth A. Handorf, et al.
Clinical Genitourinary Cancer (2014) Vol. 13, Iss. 2, pp. 142-149
Closed Access | Times Cited: 9
Matthew R. Zibelman, Peter Barth, Elizabeth A. Handorf, et al.
Clinical Genitourinary Cancer (2014) Vol. 13, Iss. 2, pp. 142-149
Closed Access | Times Cited: 9
Evaluation of second line and subsequent targeted therapies in metastatic renal cell cancer (mRCC) patients treated with first line cediranib
Suzanne Richter, Jo-An Seah, Gregory R. Pond, et al.
Canadian Urological Association Journal (2014) Vol. 8, Iss. 11-12, pp. 398-398
Open Access | Times Cited: 3
Suzanne Richter, Jo-An Seah, Gregory R. Pond, et al.
Canadian Urological Association Journal (2014) Vol. 8, Iss. 11-12, pp. 398-398
Open Access | Times Cited: 3
Using cumulative toxicity to identify the optimal second-line targeted therapy in patients with metastatic renal cell carcinoma: what’s new?
Giuseppe Di Lorenzo, Sabino De Placido
Future Oncology (2013) Vol. 10, Iss. 5, pp. 845-850
Closed Access | Times Cited: 2
Giuseppe Di Lorenzo, Sabino De Placido
Future Oncology (2013) Vol. 10, Iss. 5, pp. 845-850
Closed Access | Times Cited: 2
The Anti-Tumor Effect of Zinc on Renal Cell Carcinoma by Enhancing Autophagy
Zhihai Yu, Shaobo Wu, Qiurong Zhao, et al.
Sains Malaysiana (2022) Vol. 51, Iss. 12, pp. 4009-4018
Open Access | Times Cited: 2
Zhihai Yu, Shaobo Wu, Qiurong Zhao, et al.
Sains Malaysiana (2022) Vol. 51, Iss. 12, pp. 4009-4018
Open Access | Times Cited: 2
Concomitant Drug Treatment and Elimination in the RCC-affected Kidneys: Can We Kill Two Birds with One Stone?
Muhammad Bilal Ahmed, Salman Ul Islam, Young Sup Lee
Current Drug Metabolism (2020) Vol. 21, Iss. 13, pp. 1009-1021
Closed Access | Times Cited: 1
Muhammad Bilal Ahmed, Salman Ul Islam, Young Sup Lee
Current Drug Metabolism (2020) Vol. 21, Iss. 13, pp. 1009-1021
Closed Access | Times Cited: 1
Metastasiertes Nierenzellkarzinom: Status der Therapie 2015
Jonas Busch, Barbara Erber, Ahmed Magheli, et al.
Deutsches Ärzteblatt (2015)
Open Access
Jonas Busch, Barbara Erber, Ahmed Magheli, et al.
Deutsches Ärzteblatt (2015)
Open Access
